Sutro Biopharma, Inc. · NASDAQ:STRO

Sutro Biopharma — ASCO 2021

7 slides from Sutro Biopharma's conference presentation, June 2021

  1. Slide 1: Phase 1 Dose-Escalation Study of STRO-002 in Platinum-Resistant Ovarian Cancer

    PHASE 1 DOSE-ESCALATION STUDY OF STRO-002, AN ANTI– FOLATE-RECEPTOR ALPHA ANTIBODY DRUG CONJUGATE, IN PATIENTS WITH ADVANCED, PROGRESSIVE, PLATINUM- RESISTANT/-REFRACTORY EPITHELIAL OVARIAN CANCER R. Wendel Naumann,1 Fadi S. Braiteh,2 Lainie P. Martin,3 Erika Hamilton,4 John P. Diaz,5 Sami Diab,6 Ru

  2. Slide 2: Disclosures

    2 Disclosures Dr. Naumann has received • Consulting fees: Genentech, AstraZeneca, Clovis, Sutro, Merck, OncoMed, Janssen, and Tesaro • Research funding: Bristol Myers Squib, OncoMed, and Merck • Speaker fees: Genentech R. Wendel Naumann

  3. Slide 3: Introduction

    3 Introduction Part 1: Dose-escalation cohort in ovarian cancer • FRα is a cell surface glycoprotein overexpressed in ovarian cancer and endometrial adenocarcinoma1,2 All comers STRO-002 6.4 mg/kg ovarian cancer • STRO-002 is a novel FRα-targeting ADC with a precise drug- N = 39 STRO-002 STRO-002 5.

  4. Slide 4: Results (1)

    4 Results (1) Baseline characteristics Most frequent TEAEs > 25% by gradea All patients All safety-evaluable Overall Baseline characteristic Grade 1 Grade 2 Grade 3 Grade 4 (N = 39) patients, n (%) (N = 39) Age, median (range), years 61 (48–79) Fatigue 7 (18) 19 (49) 4 (10) 0 30 (77) Time since diag

  5. Slide 5: Results (2)

    5 Results (2) • STRO-002 exhibited clinical efficacy as demonstrated by objective responses: 1 CR, 4 PR, and 5 PRu Maximum changea in tumor target lesions in RECIST-evaluable patients treated with STRO-002 ≥ 2.9 mg/kg Q3W (N = 31) RECIST- 20% Objective evaluable response per population 0% RECIST v1.

  6. Slide 6: Results (3)

    6 Results (3) • Disease control rate was 61% and 55% at ≥ 16 and 24 weeks, respectively • Median PFS was 7.2 months (95% CI, 4.5–10.8) Treatment durationa and response in RECIST-evaluable patients treated with STRO-002 ≥ 2.9 mg/kg Q3W (N = 31) CR Individual patients treated with STRO-002 Disease con

  7. Slide 7: Conclusions

    7 Conclusions • STRO-002 is a novel FRα-targeting ADC that showed preliminary Part 2: Dose-expansion cohort in ovarian cancer clinical efficacy in patients with heavily pretreated relapsed/refractory EOC demonstrated by objective responses: 1 CR, 4 PRs, and 5 PRus All comers • STRO-002 treatment was

Sutro Biopharma — ASCO 2021 on 6ix